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Abstract
The annual Alzheimer’s Research UK (ARUK) Conference was hosted by the Manchester and North West Network
Centre on March 8–9, 2016. In this report, we provide a summary of the research presented.
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Introduction
The Alzheimer’s Research UK (ARUK) Conference 2016
offered a diverse programme, prepared by a committee
led by Nigel Hooper (University of Manchester, UK).
The programme opened with an introduction from Chris
and Jayne Roberts. Chris was diagnosed with mixed
dementia at the age of 50 and spoke about living with the
condition. Their inspiring words were followed by the
latest insights from basic and clinical research.
Frontotemporal dementia
The Conference started with an emphasis on frontotem-
poral dementia (FTD), an active area of research in
Manchester. Jennifer Whitwell (Mayo Clinic, USA) sum-
marised the different clinical syndromes of FTD and dis-
cussed the inclusion of primary progressive apraxia of
speech, progressive supranuclear palsy and corticobasal
syndrome in the FTD complex. Whitwell highlighted the
neuroanatomical associations of the FTD syndromes and
showed that neuroanatomical variability could be ex-
plained by different pathological associations which can
be predicted by patterns of atrophy on magnetic reson-
ance imaging (MRI). Specifically, Whitwell showed that
MRI could be useful for predicting underlying pathology
within patients with the behavioural variant of FTD.
Offering a neuropathological perspective, Tammaryn
Lashley (University College London (UCL), UK) showed
changes in the expression of multiple heterogeneous nu-
clear ribonucleoproteins (hnRNP) between FTD-TDP-43
and FTD-FUS subtypes, highlighting the different mech-
anisms that could underlie these diseases. Specifically,
Lashley showed that hnRNPs involved in nuclear export
and not shuttled by transportin were found in patho-
logical inclusions in FTD-FUS. Focusing on patients
with C9orf72 pathology, David Mann (University of
Manchester, UK) reported that, although the presence
and topographic distribution of dipeptide repeats may be
of diagnostic relevance, they did not relate to clinical
phenotype. Conversely, the distribution and severity of
TDP-43 pathology closely reflected clinical expression of
disease. Mann suggested that, as the severity of TDP-43
pathology is similar in bearers and non-bearers of the
C9orf72 expansion, the expansion may act as a genetic
risk factor for FTD and motor neurone disease, but with
clinical phenotype being driven by TDP-43 pathology.
Jonathan Rohrer (UCL, UK) introduced the Genetic
FTD Initiative (GENFI) 2, a five-year multi-centre study
that builds on GENFI1 but with an increased number of
sites across Europe and Canada. GENFI2 will aim to
identify robust markers of disease onset and progression
(such as cerebrospinal fluid, serum and MRI measures)
as well as the optimal time to start a disease-modifying
therapy. GENFI2 will also constitute a trial-ready cohort
of participants for future studies.
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Disease mechanisms of dementia: inflammation
Neuroinflammation represents an important component
of Alzheimer’s disease (AD) neuropathology and patho-
genesis. Delphine Boche (University of Southampton,
UK) highlighted the complexity of the microglial re-
sponse in human AD using the Cognitive Function and
Ageing Studies cohort. Her findings suggested that the
microglial specific loss of Iba-1 in AD reflected the loss
of microglial motility necessary to support the neurons;
while microglial phagocytic proteins CD68 and MSR-A
were positively associated with AD pathology and im-
paired cognitive function. In addition, the different
microglial responses observed with either Aβ or tau in
association with dementia status re-enforced that micro-
glia have a potential role in the onset of dementia. Angela
Hodges (King’s College London (KCL), UK) reported that
microglia phagocytosis was impaired in AD and that this
was magnified in post-mortem brains of TREM2 carriers
with AD. Furthermore, Hodges showed that TREM2 car-
riers with AD had impaired markers of antigen presenta-
tion—HLA and Iba-1—although microglia continued to
have an activated phenotype. Michael Heneka (DZNE,
Germany) suggested that early and focal innate immune
activation was involved at the beginning of the disease
process. He focused on NLRP3 (NACHT, LRR and PYD
domains-containing protein 3), an inflammasome protein
whose inhibition modulated microglial functions and pre-
vented the development of cognitive impairment in ani-
mal models of AD. Heneka described a retrospective
study where pioglitazone was suggested to mediate pro-
tection from dementia, via peroxisome proliferator-
activated receptor γ-mediated mechanisms. David Brough
(University of Manchester, UK) proposed the use of fena-
mates, a class of nonsteroidal anti-inflammatory drugs, to
engage targets involved in the regulation of NLRP3, in
particular interleukin (IL)-1β release. Brough showed that
fenamates could inhibit ASC (apoptosis associated speck-
like protein containing a CARD) speck formation and in-
hibit NLRP3 via inhibition of the volume-regulated anion
channel. In in vivo models, fenamates inhibited monoso-
dium urate monohydrate-induced inflammation and im-
proved the behaviour of transgenic AD mouse models,
not only when administered prophylactically but also in
mice displaying a phenotype. Jack Rivers-Auty (University
of Manchester, UK) proposed that zinc deficiency, a com-
mon population deficiency and a prevalent deficiency in
AD, exacerbated inflammation through NLRP3 and IL-1β.
Rivers-Auty presented that zinc-deficient APP-PS1 mice
had accelerated AD behavioural phenotype in Y-maze and
Morris water maze.
Disease mechanisms of dementia: vascular
Vascular changes can contribute to neurodegeneration
in a number of different dementias. Jessica Duncombe
(University of Edinburgh, UK) presented evidence to
show that cortical neurovascular coupling was progres-
sively impaired with age in wild-type mice but, surpris-
ingly, was not further impaired in the TgSwDI mouse
model of amyloid deposition. Duncombe showed that
disruption of the contact between astrocytic end-feet
and cerebral blood vessels, as well as increased micro-
glial activation, could underlie this functional impair-
ment. Focusing on patients with small vessel disease
(SVD), Laura Parkes (University of Manchester, UK) pre-
sented functional imaging data from blood oxygenation
level-dependent MR scans of 58 healthy participants
with an age range of 18–71 years and 12 patients with
SVD. The metabolic response to the Stroop task was re-
duced with age, suggesting that reduced neural activity/
density was contributing to poorer performance. Unex-
pectedly, the SVD group showed increased metabolic re-
sponse in comparison with age- or performance-matched
control groups. This could reflect increased baseline
oxygen extraction fraction in the SVD group, which could
be a compensatory mechanism to maintain oxygen
metabolism.
Disease mechanisms of dementia: amyloid and
prion
Understanding the underlying mechanisms of diseases
causing dementia can reveal novel therapeutic targets.
David Allsop (Lancaster University, UK) showed that
cytotoxicity of key misfolded proteins, such as amyloid
or prion protein and their fragments or mutant forms,
correlated with their redox activity. Mature Aβ fibrils
retained redox activity and were able to degrade H2O2
with a role for copper II (stimulatory) and/or zinc II ions
(inhibitory). This resulted in the generation of highly re-
active hydroxyl radicals, which could damage the protein
itself or neighbouring molecules. Stephen Strittmatter
(Yale, USA) presented that deletion of prion protein
(PrPC) prevented the development of memory deficits in
APPswe/PS1deltaE9 mice. Moreover, AD-related pheno-
types could be rescued by blockade of the prion protein
co-receptor, metabotropic glutamate receptor 5. Stritt-
matter argued that this mediated the link between PrPC
and the intracellular protein mediators Homer1b/c,
calcium/calmodulin-dependent protein kinase II, and
protein-tyrosine kinase 2-beta. Sebastian Brandner
(UCL, UK) discussed his recent findings on the iatro-
genic route of transmission of prion disease by treatment
of people with human growth hormone. In an autopsy
study of eight individuals with iatrogenic Creutzfeldt–
Jakob disease, aged 36–51 years, Brandner found moder-
ate to severe grey matter and vascular Aβ pathology in
four patients. Aβ depositions were typical of that seen in
AD and cerebral amyloid angiopathy and did not co-
localise with prion protein. Brandner also found Aβ
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deposits in the pituitary glands of patients who had AD-
like pathology in the brain, suggesting that Aβ seeds
were transmitted alongside the prion protein.
Disease mechanisms of dementia: tau
Tau protein is becoming an increasingly attractive target
in the search for disease-modifying treatments for AD
and other tauopathies. Marie Bondulich (KCL, UK) de-
scribed the characterisation of Tau35 mice, a novel model
expressing human derived wild-type truncated tau at less
than 10 % of the amount of endogenous mouse tau.
Treated daily with phenylbutyrate for 6 weeks, these mice
showed improved motor performance, spatial learning
and hippocampal-dependent memory. This effect was
associated with a rescue in hyperphosphorylated tau,
autophagy and lysosomal markers p62, cathepsin D and
acetylated tubulin as well as synapsin-1. Wendy Noble
(KCL, UK) observed that the presence of activated astro-
cytes and phosphorylated tau in synapses correlated with
dementia in AD and that, in mice, astrocytes activated by
Aβ modulated tau cleavage, phosphorylation, localisation
and release. Noble then presented evidence from organo-
typic 3xTg-AD brain slice cultures that tau relocalisation
and astrocyte reactivity influenced tau release and that this
could be reduced with anti-inflammatory treatment.
Disease models: induced pluripotent stem cells
Zameel Cader (Oxford, UK) introduced the StemBANCC
project, a consortium of industrial and academic partners
that collects and characterises induced pluripotent stem
cells (iPSCs) for several neurological diseases. Stem-
BANCC strives to develop strong quality control metrics,
as well as holding clinical information on individuals that
can increase the confidence of researchers that they are
working with robust, well characterised cell lines. Selina
Wray (UCL, UK) is one of the scientists developing the
iPSC model system for tauopathies. Wray reported that
the developmental regulation of tau splicing and phos-
phorylation was conserved in iPSC neurons and that ex-
tended in vitro cultures are required for the expression of
all tau isoforms. Splice-site mutations in MAPT were able
to override the developmental regulation of tau splicing
and led to the overproduction of 4R tau isoforms. Wray
noted that long-term cultures could reveal pathological
post-translational modifications. Focusing on cortical neu-
rons generated from reprogramming and differentiation of
monogenic familial AD fibroblasts, Steven Moore (ARUK
Stem Cell Research Centre, University of Cambridge, UK)
found that each class of mutation studied increased the
production of longer Aβ peptides but did so by different
mechanisms. Mutations affecting APP or an increase in its
dosage led to changes in tau levels and phosphorylation,
whereas several PSEN1 mutations did not. Moore also
reported on progress in collaboration with the labs of
Dominic Walsh (Harvard University, USA) and Michael
Rowan (Trinity College Dublin, Ireland) to prospectively
identify synaptotoxic peptides generated by stem cell
models of dementia. To date, they have identified two
distinct proteins that negatively affect synaptic function in
vivo, blocking long-term potentiation induction in
rodents.
Drug discovery and development
The value of academic drug discovery complementing
pharma efforts was made evident through a series of up-
dates from across the UK. Giovanna Mallucci (University
of Cambridge, UK) showed that rTg4510 mice show dys-
regulated PERK (RNA-activated protein kinase-like
endoplasmic reticulum kinase) signalling by 6 months of
age, associated with the onset of neurodegeneration.
Treatment with PERK inhibitor GSK2606414 prevented
further neuronal loss, reduced brain atrophy and abro-
gated the appearance of clinical signs. Importantly, Mal-
lucci also showed that phenotypic screens have revealed
two repurposed drugs acting on this pathway that are
neuroprotective in rTg4510 and prion mice. These are
safe and licensed in humans and can now be used in
clinical trials of AD and dementia. Mike O’Neill (Lilly,
UK) gave an overview of the amyloid and tau drug dis-
covery programmes at Lilly and other major pharma-
ceutical companies. Results of several phase III trials
with various amyloid therapeutic approaches will be
available in the next 2–3 years. O’Neill also spoke of tau
programmes being established as a priority aided by in-
vestment in cell and transgenic models of tauopathy and
the development of selective positron emission tomog-
raphy tracers (such as 18F-T807/AV1451) which have
the potential to act as biomarkers of disease progression
for future tau therapies. The Chief Scientific Officers of
the ARUK Drug Discovery Alliance, John Skidmore
(University of Cambridge, UK), John Davis (University of
Oxford, UK) and Paul Whiting (UCL, UK), described
the ongoing research opportunities available to academic
researchers to translate new science into drug discovery
or clinical biomarker projects. The aim of the Alliance is
to generate chemical series for target validation and as
leads for further development.
Prizes for early-career dementia scientists
Rita Guerreiro (UCL, UK) was awarded the ARUK Young
Investigator of the Year Award 2016 in recognition of her
achievements. Guerreiro reflected on her career, which in-
cluded the use of exome sequencing to identify genetic
causes of rare diseases as well as risk variants for AD such
as TREM2. Guerreiro highlighted the role of new tech-
nologies in allowing easier and faster genetic analysis and
the fact that pleiotropic events indicate shared molecular
mechanisms between neurodegenerative diseases. This
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year’s Jean Corsan Prize, recognising an outstanding scien-
tific paper in neurodegeneration published by a PhD or
MD/PhD student, went to Tobias Wauer (Laboratory of
Molecular Biology, Cambridge, UK). During his PhD,
Wauer solved the crystal structure of Pediculus humanus
PARKIN in complex with Ser65-phosphorylated ubiquitin,
revealing the molecular basis for PARKIN recruitment
and activation and opening up new avenues to identify
small-molecule PARKIN activators. Other prizes awarded
to conference attendees were: the Dick Bell Prize for
Communication to Jessica Duncombe, the David Dawbarn
Poster Prize to Patricia Vazquez Rodriguez (University of
Cambridge, UK) and the Manchester and North West
ARUK Network Centre Poster Prize to Elijah Mak
(University of Cambridge, UK).
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